

Hepatitis C: State of Medicaid Access Report Card

New Hampshire



Grade	Recommendations to Improve Patient Access
A+	<ul style="list-style-type: none">Continue to ensure broad access to HCV treatment.Remove the limitations on prescriber eligibility for exemption of prior authorization in treatment-naïve patients.

State Overview

As of July 2025, 184,143 individuals were enrolled in Medicaid and CHIP in New Hampshire.¹ It is estimated that as of 2016, 7,700 people were living with HCV in New Hampshire.² New Hampshire Medicaid operates a fee-for-service (FFS) program and contracts with managed care organizations (MCOs).³ Most beneficiaries, 98 percent, are enrolled in an MCO, and the remaining 2 percent participate in FFS.⁴ New Hampshire Medicaid contracts with three managed care organizations (MCOs): AmeriHealth Caritas New Hampshire (AmeriHealth), NH Healthy Families, and WellSense Health Plan (WellSense).⁵

The New Hampshire Medicaid Preferred Drug List lists ledipasvir/sofosbuvir, Mavyret, and sofosbuvir/velpatasvir as preferred regimens.⁶

Deductions		Policy
Prior Authorization		For treatment-naïve individuals (1-year lookback), prior authorization is not required if they are prescribed a preferred regimen. ⁷
Fibrosis Restrictions		New Hampshire Medicaid does not impose fibrosis restrictions. ⁸
Substance Use Restrictions		New Hampshire Medicaid does not impose substance use restrictions. ⁹
Prescriber Restrictions		New Hampshire Medicaid does not impose prescriber restrictions. However for treatment-naïve patients, prior authorization appears to only be waived for certain prescribers: “Drug must be prescribed by, or in consultation with, a gastroenterologist, hepatologist, infectious disease physician, or the prescriber must have completed continuing medical education on the treatment of hepatitis C.” ¹⁰
Retreatment Restrictions		New Hampshire Medicaid does not impose undue retreatment restrictions. ¹¹ For patients that are treatment experienced, the state requires that the prescription must be prescribed by or in consultation with a specialist, “or the prescriber must have completed continuing medical education on the treatment of hepatitis C.” ¹²
Access in Managed Care		All MCOs, AmeriHealth ¹³ , NH Healthy Families ¹⁴ , and WellSense ¹⁵ , appear to follow FFS criteria.
Additional Restrictions		New Hampshire Medicaid does not impose any additional restrictions. ¹⁶
Total Deductions -0		Total Score [100-Deductions] 100
		Grade A+

Contact Your State Officials

Medicaid Office¹⁷: Henry Lipman, Director Division of Medicaid Services, New Hampshire Department of Health & Human Services

129 Pleasant Street, Concord, NH 03301-6521; Telephone: (603) 271-4344

Drug Utilization Review Board¹⁸: Margaret “Peg” Clifford, NH Department of Health and Human Services

129 Pleasant Street, Concord, NH, 03301; Telephone: (603) 271-9098; Email Address: Margaret.clifford@dhhs.nh.gov

Key Sources

Preferred Drug List: [New Hampshire Medicaid Preferred Drug List \(Oct. 1, 2025\)](#)

Clinical Criteria: [New Hampshire Medicaid FFS Program, Hepatitis C Criteria \(Nov. 21, 2024\)](#)

¹ Centers for Medicare & Medicaid Services, Medicaid & CHIP in New Hampshire, <https://www.medicaid.gov/state-overviews/stateprofile.html?state=new-hampshire>.

² HepVu, Local Data: New Hampshire State Profile, <https://perma.cc/DKH4-RTDP>.

³ New Hampshire Department of Health & Human Services, Medicaid Care Management, <https://www.dhhs.nh.gov/programs-services/medicaid/medicaid-care-management>.

⁴ Kaiser Family Foundation, Share of Medicaid Population Covered Under Different Delivery Systems (July 1, 2022), <https://perma.cc/EMN8-QR8B>.

⁵ New Hampshire Department of Health & Human Services, Medicaid Care Management, <https://www.dhhs.nh.gov/programs-services/medicaid/medicaid-care-management>.

⁶ Preferred Drug List.

⁷ Clinical Criteria.

⁸ Clinical Criteria.

⁹ Clinical Criteria.

¹⁰ Clinical Criteria.

¹¹ Clinical Criteria.

¹² Clinical Criteria.

¹³ AmeriHealth Caritas New Hampshire, Prior Authorization Criteria (Jan 29, 2024), <https://perma.cc/855A-G3DA>.

¹⁴ NH Healthy Families, Medicaid Specialty Pharmacy Policies: Hepatitis C Agents (Nov. 1, 2023), <https://perma.cc/Y3CQ-4FCE>; see also Preferred Drug List, <https://pharmacy.envolvehealth.com/content/dam/centene/envolve-pharmacy-solutions/pdfs/PDL/FORMULARY-NewHampshireHealthyFamilies.pdf>.

¹⁵ WellSense, Pharmacy Policy: Hepatitis C (Jan 1, 2021), <https://bostonmedicalcenter.policytech.com/dotNet/documents/?docid=7212&public=true>; see also Medication Guide Book (Feb. 1, 2024), <https://perma.cc/K397-2BFC>.

¹⁶ Clinical Criteria.

¹⁷ National Association of Medicaid Directors, Medicaid Directors, <https://medicaiddirectors.org/who-we-are/medicaid-directors/>.

¹⁸ New Hampshire Department of Health & Human Services, Drug Utilization Review Board, Public Hearing (April 8, 2025), <https://nh.primetherapeutics.com/documents/51139/59645/Agenda%204.8.2025/931e3974-06e7-8a01-0bb4-ea2c4de6fd11>.